(.pdf) dr.ssa Antonella Ferro - Progettoeventi
(.pdf) dr.ssa Antonella Ferro - Progettoeventi
(.pdf) dr.ssa Antonella Ferro - Progettoeventi
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Lapatinib may sensitise HER2 positive cells to<br />
subsequent trastuzumab (in vitro findings)<br />
• Lapatinib counteracts the phosphorylation, ubiquitination and<br />
degradation of ErbB2<br />
• Lapatinib-induced cell surface accumulation of inactive HER2<br />
significantly enhances trastuzumab-mediated ADCC<br />
HER2<br />
Lapatinib<br />
K K K K<br />
HER2<br />
homodimer heterodimer<br />
K K K K K K K K K K<br />
ATP<br />
Dimerization, reduced phosphorylation<br />
and signaling inhibition<br />
Scaltriti M et al. Oncogene 2009; 28: 803-814.<br />
trastuzumab<br />
K = kinase domain<br />
ADCC = antibody-dependent cell cytotoxicity<br />
NK cell<br />
FcR<br />
K K<br />
Stabilization of HER2 dimers and<br />
receptor accumulation leads to ADCC
Change language